ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate | 126129-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate
• 英文别名: ethyl 1-(4-fluorophenyl)-5-methylpyrazole-3-carboxylate
• CAS: 126129-41-7
• 化学式: C₁₃H₁₃FN₂O₂
• 分子量: 248.257
• InChiKey: NDNGNMYQSWOXLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate 在 dipotassium peroxodisulfate 、 palladium diacetate 作用下， 以 三氟乙酸 、 三氟乙酸酐 为溶剂， 反应 12.0h， 以72%的产率得到ethyl 1-(4-fluoro-2-hydroxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  Palladium-Catalyzed Chelation-Assisted Regioselective Oxidative Dehydrogenative Homocoupling/Ortho-Hydroxylation in N-Phenylpyrazoles

  摘要：

  A palladium-catalyzed pyrazole-directed regioselective oxidative C(sp2)-H functionalization of the N-phenyl ring in N-phenylpyrazoles to afford either a biaryl bis-pyrazole (via dehydrogenative homocoupling) or N-(o-hydroxyphenyl)pyrazole (via C-H oxygenation) or their mixture is described. The substitutions on the N-phenyl ring and the pyrazole ring and the dilution of the reaction medium with respect to the TFA/TFAA mixture (substrate concentration) have a remarkable influence on the outcome of the reaction. It was discovered that if the reactions were performed under highly dilute conditions (ca. 10 times) then N-(o-hydroxyphenyl)pyrazoles were the major or the sole products.

  DOI：

  10.1021/acs.joc.5b00733
• 作为产物：
  描述：

  4-氟苯肼盐酸盐 、 乙酰丙酮酸乙酯 在 potassium acetate 作用下， 以 乙醇 为溶剂， 生成 ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate 、 1-(4-氟苯基)-3-甲基-1H-吡唑-5-羧酸乙酯
  参考文献：
  名称：

  WO2007/79086

  摘要：

  公开号：

文献信息

• PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
  申请人：Flynn Gary A.

  公开号：US20140228367A1

  公开（公告）日：2014-08-14

  The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

  本公开涉及式（I）的化合物及其药学上可接受的盐，作为酶调节剂，与激酶的II型抑制相兼容。
• Amide compounds and medicinal use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US07015218B1

  公开（公告）日：2006-03-21

  The present invention relates to a compound of the formula wherein R1 is substituted aryl, heteroaryl and the like, R2 and R3 are hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X′ is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

  本发明涉及一种化合物，其化学式为其中R1为取代芳基，杂环芳基等，R2和R3为氢，烷基，卤素，羟基等，Q为N，CH等，W为氢，烷基，羟基羧基烷基等，X为卤素，氰基，硝基，氨基等，X'为氢，卤素，氰基，硝基，Y为烷基，羟基，烷氧基，巯基等及其盐，以及包含所述化合物的药物。本发明的化合物显示出对活化淋巴细胞增殖的优越抑制作用，并可用作各种自身免疫性疾病的预防或治疗剂。
• AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1176140B1

  公开（公告）日：2004-12-29
• US7015218B1
  申请人：——

  公开号：US7015218B1

  公开（公告）日：2006-03-21
• US9221805B2
  申请人：——

  公开号：US9221805B2

  公开（公告）日：2015-12-29